Linnie Chang

Linnie is the Vice President of Finance at Genezen and leads the finance and accounting functions. She brings a wealth of industry experience to her role. Previously, she served as the Sr. Director of Finance at Orum Therapeutics, a clinical stage biotech company known for its novel class of protein degraders. Before that, she was the Controller at Arranta Bio, a leading CDMO for mRNA, from its inception in 2019 until its successful acquisition by Recipharm in February 2022. Linnie has also held positions at publicly traded bio-pharmaceutical companies during times of rapid growth and transformation, where she implemented processes to maximize efficiency and provide better financial visibility to internal and external stakeholders. Linnie is a Certified Public Accountant and began her career as an auditor with KPMG, where she worked with multinational SEC clients. She holds a Bachelor’s and Master’s degree in Accounting from the University of Massachusetts Amherst.

Why Genezen?
I chose to join Genezen because I am excited about the opportunity to be part of a dynamic and forward-thinking organization dedicated to improving people’s lives.

My Greatest Passion:
I’m lucky to be someone that can say “I love what I do” – I am passionate about bringing positive impact to people’s lives and have always loved numbers and their ability to tell stories. I find working with teams and translating data into insights that can drive strategic decision-making incredibly fulfilling, as it is using my skills to ultimately transform the lives of many.